Physician profile
Patrick Asiedu
NPI 1922078914
$9,901.57
in general payments reported to CMS, 2019-2025
24 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,013 · 2020: $1,747 · 2021: $2,559 · 2022: $2,764 · 2023: $673 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.97 |
| Education | $144.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,353.43 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,824.77 | 2019-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $977.84 | 2019-2023 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Sanofi-Aventis U.S. LLC | $797.73 | 2019-2022 | |
| Astellas Pharma US INC | $782.57 | 2020-2025 | Myrbetriq |
| Lilly USA, LLC | $424.42 | 2019-2023 | Mounjaro, Jardiance |
| Amgen INC. | $348.37 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $296.96 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $256.59 | 2019-2023 | Steglujan, Segluromet, Steglatro |
| Novartis Pharmaceuticals Corporation | $255.55 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $222.26 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $210.10 | 2019-2022 | |
| Abbvie INC. | $173.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.33 | 2022-2023 | Xifaxan |
| Dexcom, INC. | $156.03 | 2022-2023 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $150.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.84 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $133.29 | 2019-2020 | |
| Amarin Pharma, INC. | $76.58 | 2020-2022 | |
| Allergan, INC. | $64.73 | 2019-2020 | |
| Optinose US, INC. | $47.89 | 2019 | |
| Genentech USA, INC. | $16.22 | 2019 | |
| Pfizer INC. | $14.65 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Asiedu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.